News | March 06, 2025
Zydus Lifesciences launches ANVIMO
ANVIMO will be available in dosages of 240 mg and 480 mg
ANVIMO will be available in dosages of 240 mg and 480 mg
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025
ALS patients experience neuroinflammation and rapid neurodegeneration
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Subscribe To Our Newsletter & Stay Updated
